Skip to main content
. 2021 Nov 17;4:1296. doi: 10.1038/s42003-021-02773-z

Fig. 1. B16 melanoma is a stroma-poor tumor compared to 4T1 breast cancer.

Fig. 1

Mice were implanted with 200,000 B16F10 cells (hereby referred to as B16 or B16 melanoma) injected intradermally or 200,000 4T1 cells injected subcutaneously (n = 5 mice/group). Tumors were harvested 10 days post tumor challenge and fixed for immunohistochemistry (IHC) prior to staining with picrosirius red (PR) and alpha-smooth muscle actin (αSMA). a Representative cross sections of B16 melanoma (left) and 4T1 breast (right) stained with hematoxylin and eosin (H&E, top), PR (middle), and αSMA (bottom). b Bar graphs demonstrate quantification of the staining of either PR or αSMA ± standard deviation (SD) following analysis by Halo software with supervision from a pathologist. *p < 0.05; ****p < 0.001.